Thalidomide for the treatment of patients with myelodysplastic syndromes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-01-01

AUTHORS

C Strupp, U Germing, M Aivado, E Misgeld, R Haas, N Gattermann

ABSTRACT

We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%). More... »

PAGES

1-6

References to SciGraph publications

  • 1999-11-26. Angiogenesis in myelodysplastic syndromes in BRITISH JOURNAL OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/sj.leu.2402330

    DOI

    http://dx.doi.org/10.1038/sj.leu.2402330

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1017710244

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11840256


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anemia, Refractory", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anemia, Refractory, with Excess of Blasts", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Transfusion", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Constipation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Evaluation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fatigue", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myelomonocytic, Chronic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myelodysplastic Syndromes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peripheral Nervous System Diseases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pilot Projects", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Remission Induction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thalidomide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Venous Thrombosis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Strupp", 
            "givenName": "C", 
            "id": "sg:person.01001653715.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Germing", 
            "givenName": "U", 
            "id": "sg:person.01362464041.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Aivado", 
            "givenName": "M", 
            "id": "sg:person.0760154564.99", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760154564.99"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Misgeld", 
            "givenName": "E", 
            "id": "sg:person.01137007527.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137007527.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Haas", 
            "givenName": "R", 
            "id": "sg:person.01127414674.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411327.2", 
              "name": [
                "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gattermann", 
            "givenName": "N", 
            "id": "sg:person.01273447501.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bjc.6693515", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044899602", 
              "https://doi.org/10.1038/sj.bjc.6693515"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2002-01-01", 
        "datePublishedReg": "2002-01-01", 
        "description": "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q\u2212 as sole anomaly and three single aberrations. The median thalidomide dose was 400\u2009mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes \u2a7e1500/\u03bcl, Hb\u2009>\u200911\u2009g/dl and platelets \u2a7e100\u2009000/\u03bcl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).", 
        "genre": "article", 
        "id": "sg:pub.10.1038/sj.leu.2402330", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1097065", 
            "issn": [
              "0887-6924", 
              "1476-5551"
            ], 
            "name": "Leukemia", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "16"
          }
        ], 
        "keywords": [
          "hematological improvement", 
          "myelodysplastic syndrome", 
          "partial remission", 
          "efficacy of thalidomide", 
          "median thalidomide dose", 
          "RBC transfusion independence", 
          "treatment of patients", 
          "complex abnormal karyotype", 
          "stable disease", 
          "study patients", 
          "skin rash", 
          "progressive disease", 
          "transfusion independence", 
          "heart failure", 
          "thalidomide treatment", 
          "thalidomide dose", 
          "IWG criteria", 
          "minor response", 
          "treatment response", 
          "therapeutic benefit", 
          "patients", 
          "abnormal karyotype", 
          "cytogenetic groups", 
          "sole anomaly", 
          "normal karyotype", 
          "major response", 
          "RAEB", 
          "remission", 
          "single aberration", 
          "syndrome", 
          "disease", 
          "weeks", 
          "months", 
          "platelets", 
          "treatment", 
          "rash", 
          "response", 
          "thalidomide", 
          "CMML", 
          "karyotype", 
          "responders", 
          "dl", 
          "dose", 
          "granulocytes", 
          "median", 
          "efficacy", 
          "RAR", 
          "days", 
          "Hb", 
          "improvement", 
          "failure", 
          "group", 
          "aberrations", 
          "fatigue", 
          "RA", 
          "criteria", 
          "cases", 
          "summary", 
          "study", 
          "benefits", 
          "anomalies", 
          "independence"
        ], 
        "name": "Thalidomide for the treatment of patients with myelodysplastic syndromes", 
        "pagination": "1-6", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1017710244"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/sj.leu.2402330"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11840256"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/sj.leu.2402330", 
          "https://app.dimensions.ai/details/publication/pub.1017710244"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:54", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_359.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/sj.leu.2402330"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'


     

    This table displays all metadata directly associated to this object as RDF triples.

    246 TRIPLES      21 PREDICATES      109 URIs      100 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/sj.leu.2402330 schema:about N0bc630832707438ab5a132dd85e0d007
    2 N24a1472afc4e4862a67e24bc8dd8bbf5
    3 N2ad1834fa9e84cb59dade7bbc79492e4
    4 N32e72d82c88343279bcef28a1b749c84
    5 N43149ad94b5a40b4bd8665e22552887c
    6 N4abe486ddf1c482a9ca4734f13d5b8d3
    7 N6010978a87e8454bb08a1beee6863abe
    8 N65033e46adbd47d7a354b3947489ea72
    9 N65c4331fd8c143f7bdbb0a54ee1919e9
    10 N712dc03e00114428b83b19edc6cbd9fe
    11 N824f91d9ffb04d5ab25003dc626c09a6
    12 N8b04148f07864f61ae59fbbdc0a9a498
    13 N9117853febd541c1a6e555f807050bf7
    14 N98fc37918d3346e18d38941f7deb10eb
    15 N9bd8aefd5ae240e79f51a434d8d73095
    16 Nb024d932b8b64b2682bf014cea8c6165
    17 Nb973cf3c9eec44ae95a68c96bc0b5c1c
    18 Nd4bf5b25b5cb4632b5426f84984ca88a
    19 Nf32b806da25b4d0cbb89f6f318e23816
    20 Nf41ae0a1b58c4301a6bae278343fc6ed
    21 Nfdfd67736cc44c238d0412707b33bdc9
    22 anzsrc-for:11
    23 anzsrc-for:1102
    24 schema:author N3cf904bc10ab465c8f0cdbbbde6d68f2
    25 schema:citation sg:pub.10.1038/sj.bjc.6693515
    26 schema:datePublished 2002-01-01
    27 schema:datePublishedReg 2002-01-01
    28 schema:description We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).
    29 schema:genre article
    30 schema:isAccessibleForFree false
    31 schema:isPartOf N06a64a0ddcf34b67ace636b2a2c0811a
    32 N6ceecde6d2f1499e895e60d849c6044b
    33 sg:journal.1097065
    34 schema:keywords CMML
    35 Hb
    36 IWG criteria
    37 RA
    38 RAEB
    39 RAR
    40 RBC transfusion independence
    41 aberrations
    42 abnormal karyotype
    43 anomalies
    44 benefits
    45 cases
    46 complex abnormal karyotype
    47 criteria
    48 cytogenetic groups
    49 days
    50 disease
    51 dl
    52 dose
    53 efficacy
    54 efficacy of thalidomide
    55 failure
    56 fatigue
    57 granulocytes
    58 group
    59 heart failure
    60 hematological improvement
    61 improvement
    62 independence
    63 karyotype
    64 major response
    65 median
    66 median thalidomide dose
    67 minor response
    68 months
    69 myelodysplastic syndrome
    70 normal karyotype
    71 partial remission
    72 patients
    73 platelets
    74 progressive disease
    75 rash
    76 remission
    77 responders
    78 response
    79 single aberration
    80 skin rash
    81 sole anomaly
    82 stable disease
    83 study
    84 study patients
    85 summary
    86 syndrome
    87 thalidomide
    88 thalidomide dose
    89 thalidomide treatment
    90 therapeutic benefit
    91 transfusion independence
    92 treatment
    93 treatment of patients
    94 treatment response
    95 weeks
    96 schema:name Thalidomide for the treatment of patients with myelodysplastic syndromes
    97 schema:pagination 1-6
    98 schema:productId Nb7ffaae543f44eb9959c4f15c295cf07
    99 Ncf4315033cc041c085f2ef1f7f36666b
    100 Nf6c4fd3642934400a1b6c625214144a8
    101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017710244
    102 https://doi.org/10.1038/sj.leu.2402330
    103 schema:sdDatePublished 2022-08-04T16:54
    104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    105 schema:sdPublisher N38193dc22e174600bdd24627ebd1bb80
    106 schema:url https://doi.org/10.1038/sj.leu.2402330
    107 sgo:license sg:explorer/license/
    108 sgo:sdDataset articles
    109 rdf:type schema:ScholarlyArticle
    110 N06a64a0ddcf34b67ace636b2a2c0811a schema:issueNumber 1
    111 rdf:type schema:PublicationIssue
    112 N0bc630832707438ab5a132dd85e0d007 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Blood Transfusion
    114 rdf:type schema:DefinedTerm
    115 N24a1472afc4e4862a67e24bc8dd8bbf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Thalidomide
    117 rdf:type schema:DefinedTerm
    118 N2ad1834fa9e84cb59dade7bbc79492e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Peripheral Nervous System Diseases
    120 rdf:type schema:DefinedTerm
    121 N2ba34b65d1004b5ca19ca67a77bb3082 rdf:first sg:person.01137007527.41
    122 rdf:rest N93c5fdd062bf4647866186c7c611766c
    123 N32a9f788be904747953a7ec9099165d8 rdf:first sg:person.0760154564.99
    124 rdf:rest N2ba34b65d1004b5ca19ca67a77bb3082
    125 N32e72d82c88343279bcef28a1b749c84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Aged, 80 and over
    127 rdf:type schema:DefinedTerm
    128 N38193dc22e174600bdd24627ebd1bb80 schema:name Springer Nature - SN SciGraph project
    129 rdf:type schema:Organization
    130 N3cf904bc10ab465c8f0cdbbbde6d68f2 rdf:first sg:person.01001653715.11
    131 rdf:rest Ne35bda8dd02545a2b9b69b8b79580741
    132 N43149ad94b5a40b4bd8665e22552887c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Pilot Projects
    134 rdf:type schema:DefinedTerm
    135 N4abe486ddf1c482a9ca4734f13d5b8d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Constipation
    137 rdf:type schema:DefinedTerm
    138 N6010978a87e8454bb08a1beee6863abe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Myelodysplastic Syndromes
    140 rdf:type schema:DefinedTerm
    141 N65033e46adbd47d7a354b3947489ea72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Remission Induction
    143 rdf:type schema:DefinedTerm
    144 N65c4331fd8c143f7bdbb0a54ee1919e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Humans
    146 rdf:type schema:DefinedTerm
    147 N6ceecde6d2f1499e895e60d849c6044b schema:volumeNumber 16
    148 rdf:type schema:PublicationVolume
    149 N712dc03e00114428b83b19edc6cbd9fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Male
    151 rdf:type schema:DefinedTerm
    152 N755eb2302858462788ffae301edd320d rdf:first sg:person.01273447501.34
    153 rdf:rest rdf:nil
    154 N824f91d9ffb04d5ab25003dc626c09a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Fatigue
    156 rdf:type schema:DefinedTerm
    157 N8b04148f07864f61ae59fbbdc0a9a498 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Anemia, Refractory
    159 rdf:type schema:DefinedTerm
    160 N9117853febd541c1a6e555f807050bf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Middle Aged
    162 rdf:type schema:DefinedTerm
    163 N93c5fdd062bf4647866186c7c611766c rdf:first sg:person.01127414674.14
    164 rdf:rest N755eb2302858462788ffae301edd320d
    165 N98fc37918d3346e18d38941f7deb10eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Aged
    167 rdf:type schema:DefinedTerm
    168 N9bd8aefd5ae240e79f51a434d8d73095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Venous Thrombosis
    170 rdf:type schema:DefinedTerm
    171 Nb024d932b8b64b2682bf014cea8c6165 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Treatment Outcome
    173 rdf:type schema:DefinedTerm
    174 Nb7ffaae543f44eb9959c4f15c295cf07 schema:name pubmed_id
    175 schema:value 11840256
    176 rdf:type schema:PropertyValue
    177 Nb973cf3c9eec44ae95a68c96bc0b5c1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Female
    179 rdf:type schema:DefinedTerm
    180 Ncf4315033cc041c085f2ef1f7f36666b schema:name doi
    181 schema:value 10.1038/sj.leu.2402330
    182 rdf:type schema:PropertyValue
    183 Nd4bf5b25b5cb4632b5426f84984ca88a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Anemia, Refractory, with Excess of Blasts
    185 rdf:type schema:DefinedTerm
    186 Ne35bda8dd02545a2b9b69b8b79580741 rdf:first sg:person.01362464041.20
    187 rdf:rest N32a9f788be904747953a7ec9099165d8
    188 Nf32b806da25b4d0cbb89f6f318e23816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Drug Evaluation
    190 rdf:type schema:DefinedTerm
    191 Nf41ae0a1b58c4301a6bae278343fc6ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Leukemia, Myelomonocytic, Chronic
    193 rdf:type schema:DefinedTerm
    194 Nf6c4fd3642934400a1b6c625214144a8 schema:name dimensions_id
    195 schema:value pub.1017710244
    196 rdf:type schema:PropertyValue
    197 Nfdfd67736cc44c238d0412707b33bdc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Combined Modality Therapy
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Medical and Health Sciences
    202 rdf:type schema:DefinedTerm
    203 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Cardiorespiratory Medicine and Haematology
    205 rdf:type schema:DefinedTerm
    206 sg:journal.1097065 schema:issn 0887-6924
    207 1476-5551
    208 schema:name Leukemia
    209 schema:publisher Springer Nature
    210 rdf:type schema:Periodical
    211 sg:person.01001653715.11 schema:affiliation grid-institutes:grid.411327.2
    212 schema:familyName Strupp
    213 schema:givenName C
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11
    215 rdf:type schema:Person
    216 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
    217 schema:familyName Haas
    218 schema:givenName R
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
    220 rdf:type schema:Person
    221 sg:person.01137007527.41 schema:affiliation grid-institutes:grid.411327.2
    222 schema:familyName Misgeld
    223 schema:givenName E
    224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137007527.41
    225 rdf:type schema:Person
    226 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
    227 schema:familyName Gattermann
    228 schema:givenName N
    229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
    230 rdf:type schema:Person
    231 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
    232 schema:familyName Germing
    233 schema:givenName U
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
    235 rdf:type schema:Person
    236 sg:person.0760154564.99 schema:affiliation grid-institutes:grid.411327.2
    237 schema:familyName Aivado
    238 schema:givenName M
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760154564.99
    240 rdf:type schema:Person
    241 sg:pub.10.1038/sj.bjc.6693515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044899602
    242 https://doi.org/10.1038/sj.bjc.6693515
    243 rdf:type schema:CreativeWork
    244 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
    245 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
    246 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...